Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?

Alexander Ciurej, Elizabeth Lewis, Avanti Gupte, Eman Al-Antary, Ralph A Tripp · 2023

Read Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon? by Alexander Ciurej, Elizabeth Lewis, Avanti Gupte, Eman Al-Antary, Ralph A Tripp (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10748105.txt.

Description

Alexander Ciurej and co-authors ask whether checkpoint immunotherapy, a triumph in adult cancer, is anywhere near checkmate in children's cancers. Their 2023 review explains the drug class: antibodies that release the brakes on immune effector cells by blocking checkpoints such as CTLA-4 and PD-1. Adult success has not yet repeated in pediatrics.

The review tours current pediatric uses and active trials, borrowing leads from adult programs that might translate, and catalogues the therapy's complications. The authors propose considering checkpoint drugs as standard options in lymphoma and several solid tumors, especially when disease returns or resists other care. For childhood leukemia the evidence is not there yet. Their title question stays open, but the board, they argue, is set for an answer.

Catalog record

CREATORAlexander Ciurej, Elizabeth Lewis, Avanti Gupte, Eman Al-Antary, Ralph A Tripp
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10748105

Browse the full library · About the Tower of Babel